Andrew Weinberg
President & Chief Scientific Officer AgonOx
Seminars
Wednesday 18th November 2026
Panel Discussion: Reducing Development Risk by Evaluating Genetic Editing Strategies Shaping the Future of TIL Therapies
2:10 pm
- Comparing genome editing approaches used to enhance potency, persistence, and tumor recognition
- Reviewing safety, manufacturability, and regulatory trade-offs of engineered TIL designs
- Identifying where genetic modification adds clear clinical value vs. added complexity
- Can TIL manufacturing be designed for in vivo development rather than culturing the cells in vitro?
Wednesday 18th November 2026
Expanding TIL Clinical Activity Beyond Melanoma by Selectively Enriching Tumor Reactive T-cells
11:30 am
- Demonstrating clinical feasibility of isolating tumor reactive T-cells across multiple solid tumor types
- Sharing early phase safety and response observations from a selective TIL approach
- Informing future trial design by linking cell composition to clinical outcomes
